Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EPS (Basic) (2016 - 2025)

Northwest Biotherapeutics' EPS (Basic) history spans 16 years, with the latest figure at $0.01 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.01 for Q4 2025, up 167.34% from a year ago — trailing twelve months through Dec 2025 was -$0.04 (up 50.0% YoY), and the annual figure for FY2025 was -$0.04, up 42.86%.
  • EPS (Basic) for Q4 2025 was $0.01 at Northwest Biotherapeutics, up from -$0.02 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.16 in Q4 2021 to a low of -$4.94 in Q1 2021.
  • The 5-year median for EPS (Basic) is -$0.01 (2022), against an average of -$0.25.
  • The sharpest move saw EPS (Basic) plummeted 220.47% in 2021, then soared 167.34% in 2025.
  • Year by year, EPS (Basic) stood at $0.16 in 2021, then plummeted by 112.5% to -$0.02 in 2022, then soared by 50.0% to -$0.01 in 2023, then crashed by 100.0% to -$0.02 in 2024, then soared by 167.34% to $0.01 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at $0.01, -$0.02, and -$0.01 for Q4 2025, Q3 2025, and Q2 2025 respectively.